For more information please contact +1 (888) 605-6579

Breast Cancer

Breast cancer has seen an alarming rise in the number of victims who currently suffer from it. It has claimed countless lives. The astonishing thing is that now even some men are being affected. However the majority of the victims are women. Our mothers, sisters and wives are all at risk. If breast cancer runs in your family you are, for obvious reasons, at an increased risk. However, there is hope. Case studies have been conducted with the Live Cell Extract thymostimulin, and the results are promising.

Breast Cancer and Live Cell Therapy

Eighty-five patients with advanced breast cancer, who had previously undergone mastectomy and were currently undergoing chemotherapy, were included in a study dividing patients into 2 matching groups. One group was treated with chemotherapy and thymostimulin (live cell thymus extract) while the control group was treated with chemotherapy alone. The group receiving thymostimulin experienced approximately 1/2 the mild to severe leukopenia (reduction in number of white blood cells) as the control group.  A reduction in infections, in addition to the above results, confirmed the value of immunotherapy during chemotherapy for breast cancer.

A similar study using thymostimulin found no significant statistical differences in immunologic or hematologic values between those receiving chemotherapy alone or with thymostimulin.  However, the researchers observed that administration of the thymic hormone appeared to protect the bone marrow, and the subjects receiving thymostimulin had a lower incidence of side effects than the untreated group.

Another study involving the use of thymus extracts with breast cancer included 26 women suffering from breast carcinoma who had previously undergone mastectomy 1 to 2 years before the study began. Most had also undergone a removal of the underarm tissue.  Each subject received intramuscular injections of Thymus Extract Mulli twice weekly for 4 to 6 weeks. All subjects were monitored using the carcinoembryonic antigen (a glycoprotein involved in cell adhesion) test. Results showed a reduction of carcinoembryonic antigen values in approximately 70% of the cases treated with thymus extracts compared to 47% for controls. The authors concluded that because of its effectiveness and lack of side effects, immunotherapy is valuable and should be seriously considered as a therapy in breast cancer.